{"id":3120,"date":"2021-01-08T19:23:50","date_gmt":"2021-01-09T03:23:50","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=3120"},"modified":"2021-01-11T19:24:55","modified_gmt":"2021-01-12T03:24:55","slug":"interleukin-6-receptor-antagonists-in-critically-ill-patients-with-covid-19","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/01\/08\/interleukin-6-receptor-antagonists-in-critically-ill-patients-with-covid-19\/","title":{"rendered":"Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19"},"content":{"rendered":"<p><i>[pre-print; not peer-reviewed] <\/i>A randomized trial of the IL-6 receptor antagonists tocilizumab and sarilumab showed better patient outcomes, including 90-day survival and time to discharge, in critically ill adult COVID-19 patients who were receiving respiratory or cardiovascular organ support in intensive care units. According to this preliminary report from the randomized trial, in-hospital mortality was 28% (98\/350) for tocilizumab, 22% (10\/45) for sarilumab, and 36% (142\/397) among controls. The authors also found greater treatment effects for patients treated with either IL-6 receptor antagonist in combination with corticosteroids.<\/p>\n<p><i>Gordon et al. (Jan 7, 2021). Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. Pre-print downloaded Jan 8 from <\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.01.07.21249390\">https:\/\/doi.org\/10.1101\/2021.01.07.21249390<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[pre-print; not peer-reviewed] A randomized trial of the IL-6 receptor antagonists tocilizumab and sarilumab showed better patient outcomes, including 90-day survival and time to discharge, in critically ill adult COVID-19 patients who were receiving respiratory or cardiovascular organ support in intensive care units. According to this preliminary report from the randomized trial, in-hospital mortality was&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/01\/08\/interleukin-6-receptor-antagonists-in-critically-ill-patients-with-covid-19\/\">Read more<\/a><\/div>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[28],"topic":[19],"class_list":["post-3120","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-treatment","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/3120","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=3120"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/3120\/revisions"}],"predecessor-version":[{"id":3121,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/3120\/revisions\/3121"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=3120"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=3120"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=3120"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=3120"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}